Brief: Adial Pharmaceuticals Granted End Of Phase 2 Meeting From FDA
08/05/2025 16:03
May 8 (Reuters) - Adial Pharmaceuticals Inc ADIL.O: ADIAL PHARMACEUTICALS GRANTED END OF PHASE 2 MEETING FROM THE U.S. FOOD AND DRUG ADMINISTRATION ADIAL PHARMACEUTICALS INC - FDA MEETING SCHEDULED FOR JULY 25, 2025 Source text: ID:nGNX53XlvP Further company coverage: ADIL.O ((Reuters.Briefs@thomsonreuters.com))
Recent news on Adial Pharmaceuticals
See all newsBrief: Adial Pharmaceuticals Announces Name Change To Azora Therapeutics
Brief: Adial Pharmaceuticals Announces Planned Appointment Of Celia Economides As Chief Financial Officer
Brief: Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Adial Pharmaceuticals - Proposed Resale Of Up To 25,148,970 Shares Of Common Stock By Selling Stockholders - SEC Filing
Brief: Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)